Compare the biosimilar markets in Europe and the US. Learn why Europe adopted biosimilars earlier, how FDA regulations differ from EMA, and what the future holds for drug costs.
Lot-to-lot variability is a natural part of biologics and biosimilars due to their complex, cell-based production. Unlike generics, biosimilars aren't exact copies - but they're proven safe and effective. Learn how regulators, labs, and manufacturers manage this variation.